<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32327647</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>02</Month>
        <Day>02</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>04</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2056-676X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>6</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Apr</Month>
              <Day>23</Day>
            </PubDate>
          </JournalIssue>
          <Title>Nature reviews. Disease primers</Title>
          <ISOAbbreviation>Nat Rev Dis Primers</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Rheumatoid arthritis Primer - behind the scenes.</ArticleTitle>
        <Pagination>
          <StartPage>32</StartPage>
          <MedlinePgn>32</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41572-020-0168-y</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Smolen</LastName>
            <ForeName>Josef S</ForeName>
            <Initials>JS</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Rheumatology, Medical University of Vienna, Vienna, Austria. josef.smolen@meduniwien.ac.at.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>04</Month>
          <Day>23</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Nat Rev Dis Primers</MedlineTA>
        <NlmUniqueID>101672103</NlmUniqueID>
        <ISSNLinking>2056-676X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D018501" MajorTopicYN="N">Antirheumatic Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001172" MajorTopicYN="N">Arthritis, Rheumatoid</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName>
          <QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32327647</ArticleId>
        <ArticleId IdType="doi">10.1038/s41572-020-0168-y</ArticleId>
        <ArticleId IdType="pii">10.1038/s41572-020-0168-y</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Smolen, J. S. et al. Rheumatoid arthritis. Nat. Rev. Dis. Primers 4, 18001 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrdp.2018.1</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann. Rheum. Dis. https://doi.org/10.1136/annrheumdis-2019-216655 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2019-216655</ArticleId>
            <ArticleId IdType="pubmed">32398283</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lund Hetland, M. et al. A multicenter randomized study in early rheumatoid arthritis to compare active conventional therapy versus three biological treatments: 24 week efficacy and safety results of the NORD-STAR Trial [abstract L09]. Arthritis Rheumatol. 71 (Suppl. 10), 5237–5240 (2019).</Citation>
        </Reference>
        <Reference>
          <Citation>Croft, A. P. et al. Distinct fibroblast subsets drive inflammation and damage in arthritis. Nature 570, 246–251 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-019-1263-7</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aletaha, D. &amp; Smolen, J. S. Remission in rheumatoid arthritis: missing objectives by using inadequate DAS28 targets. Nat. Rev. Rheumatol. 15, 633–634 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41584-019-0279-6</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
